Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade

Glioblastoma (GBM) accounts for more than 50% of all primary malignancies of the brain. Current standard treatment regimen for GBM includes maximal surgical resection followed by radiation and adjuvant chemotherapy. However, due to the heterogeneity of the tumor cells, tumor recurrence is often inev...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers Ročník 13; číslo 15; s. 3686
Hlavní autoři: Ho, Rachel L. Y., Ho, Ivy A. W.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Basel MDPI AG 22.07.2021
MDPI
Témata:
Angiogenesis
Brain cancer
Brain tumors
Cancer therapies
Chemotherapy
Drug development
Genes
Glioblastoma
Glioma
Hypoxia
Immune checkpoint
Immunotherapy
Medical prognosis
Melanoma
Metabolism
Metastases
Mutation
Patients
Prognosis
Protein-tyrosine kinase
Radiation therapy
Review
Stem cells
Tumor cells
Tumors
Vascular endothelial growth factor
ISSN:2072-6694, 2072-6694
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Glioblastoma (GBM) accounts for more than 50% of all primary malignancies of the brain. Current standard treatment regimen for GBM includes maximal surgical resection followed by radiation and adjuvant chemotherapy. However, due to the heterogeneity of the tumor cells, tumor recurrence is often inevitable. The prognosis of patients with glioma is, thus, dismal. Glioma is a highly angiogenic tumor yet immunologically cold. As such, evolving studies have focused on designing strategies that specifically target the tyrosine kinase receptors of angiokines and encourage immune infiltration. Recent promising results from immunotherapies on other cancer types have prompted further investigations of this therapy in GBM. In this article, we reviewed the pathological angiogenesis and immune reactivity in glioma, as well as its target for drug development, and we discussed future directions in glioma therapy.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13153686